PRDM16 and breast carcinoma: DLG5 has been reported to be a suppressor of CSC-like properties in breast cancer cells22; and PRDM16 functions as a tumor suppressor by inhibiting the transcription of mucin4 (MUC4), which is associated with trastuzumab resistance and CSC-like properties of cancer cells23,24.